AUTL:NSD-Autolus Therapeutics plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 12.77

Change

0.00 (0.00)%

Market Cap

USD 0.65B

Volume

0.05M

Average Target Price

USD 26.40 (+106.73%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Company Website : http://www.autolus.com

Address : Forest House, London, United Kingdom, W12 7RZ

Employees : 290

Fiscal Year End : September

Currency: USD

Country : USA

Technical Indicators

Beta : 1.95

52 Week High : 17.19

Short Ratio : 4.13

52 Week Low : 3.00

Shorted Shares : 642,511

200 Day Moving Average : 11.97

Shorted Shares Previous Month : 763,930

50 Day Moving Average : 14.43

Shares Held By Insiders : 266.3%

Short Percentage : 1.00%

Shares Held by Institutions : 28.13%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD69.85B 33.27 26.59
REGN Regeneron Pharmaceuticals, Inc

N/A

 USD61.08B 21.61 16.69
SGEN Seattle Genetics, Inc

N/A

 USD32.18B N/A N/A
MRNA Moderna, Inc

N/A

 USD27.41B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD25.08B 29.87 27.00
BGNE BeiGene, Ltd

N/A

 USD24.87B N/A N/A
RPRX Royalty Pharma plc

N/A

 USD24.33B 36.15 9.83
GMAB Genmab A/S

N/A

 USD23.46B 28.02 3.06
IMMU Immunomedics, Inc

N/A

 USD19.73B N/A N/A
INCY Incyte Corporation

N/A

 USD18.93B 47.64 35.20

ETFs Containing AUTL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.26% 50% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.26% 50% F 55% F
Trailing 12 Months  
Capital Gain 6.42% 44% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.42% 44% F 62% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -23.67% N/A N/A 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.67% N/A N/A 8% F
Risk Return Profile  
Volatility (Standard Deviation) 32.45% N/A N/A 43% F
Risk Adjusted Return -72.92% N/A N/A 8% F
Market Capitalization 0.65B 70% C- 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.56 68% D+ 44% F
Price / Cash Flow Ratio -6.40 56% F 77% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -29.62% 82% B- 32% F
Return on Invested Capital -52.02% 60% D- 18% F
Return on Assets -22.28% 64% D 18% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.13 50% F 40% F
Short Percent N/A N/A N/A N/A N/A
Beta 1.95 28% F 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector